Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

NADOLOL

NFPA

PRODUCT USE

A beta- adrenoreceptor blocking agent used in the treatment of cardiac arrhythmias, to
improve tolerance to exercise in patients with angina pectoris, in ventricular
fibrillation when counter- shock can not be employed and in the treatment of hypertension.
Also used in migraine prophylaxis. Normally given by mouth. Classified as non-
cardioselective and is reported to lack intrinsic sympathomimetic and membrane-
stabilising activity. The principle effect of beta- adrenoreceptor blockade is to reduce
cardiac activity by reducing the rate and force of contraction.

SYNONYMS

C17-H27-N-O4, C17-H27-N-O4, "2, 3-naphthalenediol, 5-[3-((1, 1-dimethylethyl)amino)-2-
hydroxypropoxy]-", "2, 3-naphthalenediol, 5-[3-((1, 1-dimethylethyl)amino)-2-
hydroxypropoxy]-", "1, 2, 3, 4-tetrahydro-", "1, 2, 3, 4-tetrahydro-", "1-(tert-
butylamino)-3-[(5, 6, 7, 8-tetrahydro-cis-6, 7-dihydroxy-1-naphthyl)-", "1-(tert-
butylamino)-3-[(5, 6, 7, 8-tetrahydro-cis-6, 7-dihydroxy-1-naphthyl)-", oxy]-2-propanol,
oxy]-2-propanol, "5-[3-((1, 1-dimethylethyl)amino)-2-hydroxypropoxy]-1, 2, 3, 4-
tetrahydro-2, 3-", "5-[3-((1, 1-dimethylethyl)amino)-2-hydroxypropoxy]-1, 2, 3, 4-
tetrahydro-2, 3-", naphthalenediol, "2, 3-cis-1, 2, 3, 4-tetrahydro-5-[(2-hydroxy-3-tert-
butylamino)propoxy]-2, 3-", "2, 3-cis-1, 2, 3, 4-tetrahydro-5-[(2-hydroxy-3-tert-
butylamino)propoxy]-2, 3-", Corgard, Corgaretic, Corzide, Solgol, SQ-11725, "beta-
adrenoreceptor blocker"

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

May cause SENSITIZATION by skin contact.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Accidental ingestion of the material may be damaging to the health of the individual.  Side effects from beta-locking agents include nausea, vomiting, disturbance of of the gastrointestinal tract, fatigue and dizziness. The nervous system may be involved, causing depression, delirium, stoppage of breathing, confusion, psychosis, motor abnormalities, coma, visual disturbance and insomnia. Cardiovascular effects include slowing of pulse, low blood pressure, and heart failure. Other adverse effects include blood disorders, and allergic reactions characterized by skin rash. Other effects include sexual dysfunction, allergic reactions, weight gain, hair loss, muscle disorders, dry eyes and inflammation of the mouth cavity. The signs of overdose usually appear rapidly (within 1-2 hours) and sometimes death occurs.  

EYE

  There is some evidence that material may produce eye irritation in some persons and produce eye damage 24 hours or more after instillation. Moderate inflammation may be expected with redness; conjunctivitis may occur with prolonged exposure.  Eye absorption of beta blockers can reduce the pressure in the eye and causesystemic toxicity.  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.  

INHALED

  The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified using animal models). Nevertheless, adverse effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.  

CHRONIC HEALTH EFFECTS

  Skin contact with the material is more likely to cause a sensitization reaction in some persons compared to the general population.  Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.  Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung. Prime symptom is breathlessness; lung shadows show on X-ray.  Prolonged use of beta blockers can result in dry mouth, taste distortion, heartburn, stomach pain, nausea, vomiting, loss of appetite, bloating, flatulence, and diarrhea or constipation. The nervous system may be affected by fatigue, headache, dizziness, lethargy, depression, "pins and needles", reduced or increased sensation, anxiety, nervousness, poor concentration, sleep loss and nightmares or bizarre dreams. Eye effects include irritation, discomfort, drying, burning sensation, inflammation of the conjunctiva, impaired vision and reduction in eye pressure. Cardiovascular effects include a tight chest pain, heart failure, heart block, claudication and stroke, with chest pain, pallor, shortness of breath, flushing and fainting. Respiratory system effects include blocked nose, cough, crackling sounds, wheezing and lung scarring. Other effects recorded include renal and mesenteric arterial thrombosis, renal failure, ischaemic colitis, fibrosis in the , acute pancreatitis, enlarged liver, elevated liver enzymes, altered blood lipids, high blood glucose, impotence or diminished sex drive, painful urination, urination at night, and urinary retention or frequent urination. Allergic reactions include, fever, inflammation of the pharynx, sore throat, throat spasms and respiratory arrest. Effects on the skin include itchiness, pigmentation, necrosis and a purple color.  Nadolol was not carcinogenic in animal studies and was not mutagenic when tested in combination with bendroflumethiazide. Nadolol was embryotoxic and foetotoxic when administered to rabbits in high doses but not in hamsters or rats.